Results 21 to 30 of about 10,236,148 (357)

Striatal astrocytes act as a reservoir for L-DOPA.

PLoS ONE, 2014
L-DOPA is therapeutically efficacious in patients with Parkinson's disease (PD), although dopamine (DA) neurons are severely degenerated. Since cortical astrocytes express neutral amino acid transporter (LAT) and DA transporter (DAT), the uptake and ...
Masato Asanuma, Ikuko Miyazaki, Shinki Murakami, Francisco J Diaz-Corrales, Norio Ogawa   +4 more
doaj   +1 more source

Table1_Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model.doc

, 2022
The pharmacological manipulation of neuroinflammation appears to be a promising strategy to alleviate l-DOPA-induced dyskinesia (LID) in Parkinson’s disease (PD).
Patrick Pierre Michel (2019922), Rita Raisman-Vozari (262104), Mariza Bortolanza (6591551), Elaine Del Bel (675995), Maurício dos Santos Pereira (819420), Glauce Crivelaro do Nascimento (14162190)   +5 more
core   +1 more source

Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity

Frontiers in Molecular Neuroscience, 2018
Until now, the dopamine (DA) precursor, L-3,4-dihydroxyphenylalanine (L-DOPA), remains the gold standard effective drug therapy for Parkinson’s disease (PD) patients.
Di-Sheng Lu, Ce Chen, Ya-Xin Zheng, Dai-Di Li, Guo-Qing Wang, Jie Liu, Jingshan Shi, Feng Zhang   +7 more
doaj   +1 more source

Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease

Neurobiology of Disease, 2011
The therapeutic benefit of L-DOPA is commonly attributed to restoration of dopamine (DA) extracellular levels in the striatum of Parkinsonian patients. However, the loss of efficacy of L-DOPA after chronic use is paradoxically associated with a similar ...
Sylvia Navailles, Bernard Bioulac, Christian Gross, Philippe De Deurwaerdère   +3 more
doaj   +1 more source

Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats

Frontiers in Behavioral Neuroscience, 2014
Bradykinesia (slowness of movement) and other characteristic motor manifestations of Parkinson’s disease (PD) are alleviated by treatment with L-dihydroxyphenylalanine (L-DOPA).
Stefania eSgroi, Stefania eSgroi, Alain eKaelin-Lang, Christine eCapper-Loup   +3 more
doaj   +1 more source

Evidence of d-phenylglycine as delivering tool for improving l-dopa absorption

Journal of Biomedical Science, 2010
Background l-Dopa has been used for Parkinson's disease management for a long time. However, its wide variety in the rate and the extent of absorption remained challenge in designing suitable therapeutic regime.
Wang Chun-Li, Fan Yang-Bin, Lu Hsiao-Hwa, Tsai Tung-Hu, Tsai Ming-Cheng, Wang Hui-Po   +5 more
doaj   +1 more source

Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease

Neurobiology of Disease, 2010
Benefit and motor side effects of l-DOPA in Parkinson's disease have been related to dopamine transmission in the striatum. However, the putative involvement of serotonergic neurons in the dopaminergic effects of l-DOPA suggests that the striatum is not ...
Sylvia Navailles, Bernard Bioulac, Christian Gross, Philippe De Deurwaerdère   +3 more
doaj   +1 more source

Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. [PDF]

PLoS ONE, 2008
L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a progressive sensitization through repeated L-dopa exposures. The MPTP macaque model was used to study
Birger Scholz, Marcus Svensson, Henrik Alm, Karl Sköld, Maria Fälth, Kim Kultima, Céline Guigoni, Evelyne Doudnikoff, Qin Li, Alan R Crossman, Erwan Bezard, Per E Andrén   +11 more
doaj   +1 more source

Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson’s disease

Frontiers in Systems Neuroscience, 2010
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is characterized by dopamine depletion in the striatum. One consistent pathophysiological hallmark of PD is an increase in spontaneous oscillatory activity in the basal ganglia ...
Youngbin Kwak, Scott Peltier, Nicolaas Bohnen, Nicolaas Bohnen, Martijn Müller, Praveen Dayalu, Rachael D Seidler, Rachael D Seidler, Rachael D Seidler, Rachael D Seidler   +9 more
doaj   +1 more source

Cost-Effective Production of L-DOPA by Tyrosinase-Immobilized Polyhydroxyalkanoate Nanogranules in Engineered Halomonas bluephagenesis TD01

Molecules, 2021
3,4-dihydroxyphenyl-L-alanine (L-DOPA) is a preferred drug for Parkinson’s disease, with an increasing demand worldwide that mainly relies on costly and environmentally problematic chemical synthesis.
Jiping Zhao, Ganqiao Ran, Mengmeng Xu, Xiaoyun Lu, Dan Tan   +4 more
doaj   +1 more source